Goldman Sachs Resumes Coverage on SXC Health Solutions (SXCI) at Buy; Strong Growth Beyond Integration
Tweet Send to a FriendGet Alerts SXCI Hot Sheet
Price: $93.02 --0%
Rating Summary:
13 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
13 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade SXCI Now!
Goldman Sachs resumes coverage on SXC Health Solutions (NASDAQ: SXCI) with a Buy. PT $120.00.
Analyst, Robert P. Jones, said, "Beyond nearly doubling revenue/EBITDA, the additional scale should allow SXC to be more competitive. While there are clear benefits from this deal, the more important issue is appropriate valuation given the larger base to grow off of and comps from the top PBM operators. Under our assumptions, we believe SXC can grow earnings beyond the integration period at 19%, which doesn’t include additional M&A, something management has been clear is still very much part of the story."
Jones lowers FY12 EPS estimate from $2.43 to $2.40, but raises FY13 from $3.19 to $3.74, and FY14 from $3.89 to $5.04. He believes SXC can get about $1 billion in net new business wins each year (about 1%) from top PBM businesses like Express Scripts (Nasdaq: ESRX)(Conviction-List Buy) and CVS (NYSE: CVS)(Buy).
For an analyst ratings summary and ratings history on SXC Health Solutions click here. For more ratings news on SXC Health Solutions click here.
Shares of SXC Health Solutions closed at $96.37 yesterday, with a 52 week range of $40.36-$104.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Robert P. Jones, said, "Beyond nearly doubling revenue/EBITDA, the additional scale should allow SXC to be more competitive. While there are clear benefits from this deal, the more important issue is appropriate valuation given the larger base to grow off of and comps from the top PBM operators. Under our assumptions, we believe SXC can grow earnings beyond the integration period at 19%, which doesn’t include additional M&A, something management has been clear is still very much part of the story."
Jones lowers FY12 EPS estimate from $2.43 to $2.40, but raises FY13 from $3.19 to $3.74, and FY14 from $3.89 to $5.04. He believes SXC can get about $1 billion in net new business wins each year (about 1%) from top PBM businesses like Express Scripts (Nasdaq: ESRX)(Conviction-List Buy) and CVS (NYSE: CVS)(Buy).
For an analyst ratings summary and ratings history on SXC Health Solutions click here. For more ratings news on SXC Health Solutions click here.
Shares of SXC Health Solutions closed at $96.37 yesterday, with a 52 week range of $40.36-$104.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: UBS Starts Insmed (INSM) at Buy
- Deutsche Bank Starts Quintiles (Q) at Buy
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Mergers and Acquisitions, New CoverageRelated Entities
Goldman Sachs, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
